Faron Pharmaceuticals appoints chief business officer.

Faron Pharmaceuticals announced the appointment of Ralph Hughes as its chief business officer on Wednesday, effective 28 May, as the clinical-stage biopharma firm sharpened its focus on commercial strategy, business development and market access.

Faron Pharmaceuticals Oy (DI)
21 May 2025 14:31:28

Source: Sharecast

Hughes would join both the management team and the business development committee.

The AIM-traded firm said he would bring extensive experience in commercial strategy and market access from senior roles at PharmaVentures, Mundipharma and Pfizer.

At Mundipharma, he led commercial launch planning for pipeline assets, while at Pfizer he worked on global pricing and access strategies across various disease areas.

He holds an MSc in public health and health economics from the London School of Hygiene and Tropical Medicine.

Faron, which is developing next-generation immunotherapies, said Hughes’ appointment was made at a pivotal time, as it advanced its clinical pipeline and looked to expand partnerships.

Chief executive officer Dr Juho Jalkanen said Hughes’ leadership and track record aligned closely with Faron’s strategic growth plans.

At 1047 BST, shares in Faron Pharmaceuticals were up 2.71% at 227p.

Reporting by Josh White for Sharecast.com.

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.